

Re: Your request made under the Freedom of Information Act 2000

I have a Freedom of Information request for prescribing in Crohn's Disease and Ulcerative Colitis.

- 1) Could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Crohn's Disease, for each of the following treatments:

Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Ustekinumab [Stelara]
Vedolizumab [Entyvio]

- 2) Also, could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Ulcerative Colitis, for each of the following treatments:

Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]
Golimumab [Simponi]
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Tofacitinib [Xeljanz]
Ustekinumab [Stelara]
Vedolizumab [Entyvio]

If you are unable to answer my questions with breakdown by specified conditions then please provide me with the numbers of patients treated in the last 3 months (October to December 2019 inclusive if possible) with the above drugs, regardless of disease/indication.

Adalimumab (Amgevita)	410
Adalimumab (Humira)	42
Golimumab	61
Infliximab (Remicade)	13
Infliximab (Remsima)	185
TOFACITINIB 5 mg Tablets	9
Ustekinumab	38
Vedolizumab	68